Patents by Inventor Daniel Oehlrich
Daniel Oehlrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240279223Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.Type: ApplicationFiled: June 30, 2022Publication date: August 22, 2024Inventors: Daniel OEHLRICH, Michael Eric MURATORE, Laura PEREZ BENITO, Joseph Elisabeth LEENAERTS, Gary John TRESADERN, Michiel Luc M VAN GOOL, Nina VAN OPDENBOSCH, Mohamed LAMKANFI
-
Publication number: 20240239757Abstract: Provided are novel compounds for use as inhibitors of NLRP3 inflammasomeproduction, wherein such compounds are as defined by compounds of formula (I) wherein, R1, R2 and R3a and R3b are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.Type: ApplicationFiled: April 28, 2022Publication date: July 18, 2024Inventors: Daniel OEHLRICH, Nina VAN OPDENBOSCH, Mohamed LAMKANFI, Santiago CANELLAS ROMAN, Michiel Luc Maria VAN GOOL, Alejandro DIÉGUEZ-VÁZQUEZ
-
Publication number: 20240174670Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2, R3a, R3b and R4 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.Type: ApplicationFiled: March 3, 2022Publication date: May 30, 2024Inventors: Daniel OEHLRICH, Nina VAN OPDENBOSCH, Mohamed LAMKANFI, Michael Eric MURATORE, Maria Lourdes LINARES DE LA MORENA, Manuel Jesús ALCÁZAR VACA, Michiel Luc Maria VAN GOOL
-
Publication number: 20240109905Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2, R3 and R4 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.Type: ApplicationFiled: March 3, 2022Publication date: April 4, 2024Inventors: Daniel OEHLRICH, Nina VAN OPDENBOSCH, Mohamed LAMKANFI, Michael Eric MURATORE, Dries VAN ROMPAEY, Maria LINARES DE LA MORENA, Manuel Jesús ALCÁZAR VACA, Michiel Luc Maria VAN GOOL
-
Publication number: 20240043450Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.Type: ApplicationFiled: September 23, 2021Publication date: February 8, 2024Inventors: Daniel OEHLRICH, Nina VAN OPDENBOSCH, Michiel Luc Maria VAN GOOL, Dries VAN ROMPAEY, Gary John TRESADERN, Josep LLAVERIA CROS, Mohamed LAMKANFI
-
Publication number: 20230391756Abstract: The invention relates to novel compounds for use as inhibitors of NL-RP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.Type: ApplicationFiled: September 23, 2021Publication date: December 7, 2023Inventors: Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Joseph Elisabeth LEENAERTS, Michael Eric MURATORE, Gary John TRESADERN, Mohamed LAMKANFI, Nina VAN OPDENBOSCH, Robert Than HENDRICKS
-
Publication number: 20230203064Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.Type: ApplicationFiled: April 23, 2021Publication date: June 29, 2023Inventors: Daniel OEHLRICH, Nina VAN OPDENBOSCH, Mohamed LAMKANFI, Alejandro DIÉGUEZ-VÁZQUEZ, Michiel Luc Maria VAN GOOL, Santiago CAÑELLAS ROMAN
-
Publication number: 20230202989Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.Type: ApplicationFiled: May 27, 2021Publication date: June 29, 2023Inventors: Michael Eric MURATORE, Nina VAN OPDENBOSCH, Joseph Elisabeth LEENAERTS, Mohamed LAMKANFI, Gary John TRESADERN, Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Laura PEREZ BENITO
-
Publication number: 20230203044Abstract: The invention relates to novel compounds for use as in-hibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.Type: ApplicationFiled: April 15, 2021Publication date: June 29, 2023Inventors: Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Nina VAN OPDENBOSCH, Mohamed LAMKANFI, Josep LLAVERIA CROS, Carlos Manuel MARTINEZ VITURRO, Dries VAN ROMPAEY
-
Publication number: 20230183249Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2, R3a and R3b are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.Type: ApplicationFiled: April 29, 2021Publication date: June 15, 2023Inventors: Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Juan Antonio VEGA RAMIRO, Mohamed LAMKANFI, Nina VAN OPDENBOSCH
-
Publication number: 20230183248Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I), Formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.Type: ApplicationFiled: April 15, 2021Publication date: June 15, 2023Inventors: Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Nina VAN OPDENBOSCH, Mohamed LAMKANFI, Joseph Elisabeth LEENAERTS, Carlos Manuel MARTINEZ VITURRO, Michael Eric MURATORE
-
Publication number: 20230099293Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: December 18, 2020Publication date: March 30, 2023Applicant: JANSSEN PHARMACEUTICA NVInventors: José Manuel BARTOLOMÉ-NEBREDA, Petrus Jacobus Johannes Antonius BUIJNSTERS, Ana Isabel DE LUCAS OLIVARES, Joseph Elisabeth LEENAERTS, Carolina MARTINEZ LAMENCA, Daniel OEHLRICH, Andrés Avelino TRABANCO-SUÁREZ, Yves Emiel M VAN ROOSBROECK, Adriana Ingrid VELTER
-
Publication number: 20230058733Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.Type: ApplicationFiled: December 18, 2020Publication date: February 23, 2023Applicant: JANSSEN PHARMACEUTICA NVInventors: José Manuel BARTOLOMÉ-NEBREDA, Petrus Jacobus Johannes Antonius BUIJNSTERS, Joseph Elisabeth LEENAERTS, Carolina MARTINEZ LAMENCA, Daniel OEHLRICH, Andrés Avelino TRABANCO-SUÁREZ, Yves Emiel M VAN ROOSBROECK, Adriana Ingrid VELTER
-
Publication number: 20210284659Abstract: The present invention relates to tricyclic inhibitors of beta-secretase having the structure shown in Formula (I) and (II) and the tautomers and the stereoisomeric forms thereof, wherein the radicals are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease, dementia associated with beta-amyloid, age-related macular degeneration, type 2 diabetes and other metabolic disorders.Type: ApplicationFiled: March 6, 2018Publication date: September 16, 2021Inventors: Ann Marleen Vos, Daniel Oehlrich, Henricus Jacobus Maria Gijsen, Karl Shawn Watts, Sathesh Pangala Bhat, Peter Jacobus Johannes Antonius Buijnsters, Sven Franciscus Anna Van Brandt, Jesús Manuel Alcázar-Vaca
-
Publication number: 20210277003Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: September 9, 2021Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Carolina Martinez Lamenca, Joseph Elisabeth Leenaerts, Daniel Oehlrich, Petrus Jacobus Johannes Antonius Buijnsters, Adriana Ingrid Velter, Yves Emiel Maria Van Roosbroeck
-
Patent number: 11053248Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.Type: GrantFiled: October 31, 2017Date of Patent: July 6, 2021Assignee: Janssen Pharmaceutica NVInventors: Yves Emiel Maria Van Roosbroeck, Petrus Jacobus Johannes Antonius Buijnsters, Gary John Tresadern, Edgar Jacoby, Daniel Oehlrich, Henricus Jacobus Maria Gijsen
-
Publication number: 20210130352Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: May 6, 2021Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Joseph Elisabeth Leenaerts, Daniel Oehlrich, Petrus Jacobus Johannes Antonius Buijnsters, Carolina Martinez Lamenca, Adriana Ingrid Velter, Yves Erniel Maria Van Roosbroeck
-
Publication number: 20200048260Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.Type: ApplicationFiled: October 31, 2017Publication date: February 13, 2020Applicant: Janssen Pharmaceutica NVInventors: Yves Emiel Maria Van Roosbroeck, Petrus Jacobus Johannes Antonius Buijnsters, Gary John Tresadern, Edgar Jacoby, Daniel Oehlrich, Henricus Jacobus Maria Gijsen
-
Publication number: 20200010482Abstract: The present invention relates to tricyclic inhibitors of beta-secretase having the structure shown in Formula (I) and (II) and the tautomers and the stereoisomeric forms thereof, wherein the radicals are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease, dementia associated with beta-amyloid, age-related macular degeneration, type 2 diabetes and other metabolic disorders.Type: ApplicationFiled: March 6, 2018Publication date: January 9, 2020Inventors: Ann Marleen Vos, Daniel Oehlrich, Henricus Jacobus Maria Gijsen, Karl Shawn Watts, Sathesh Pangala Bhat, Frans Maria Alfons Van den Keybus
-
Publication number: 20190389882Abstract: The present invention relates to tricyclic inhibitors of beta-secretase having the structure shown in Formula (I) and (II) wherein the radicals are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease, dementia associated with beta-amyloid, age-related macular degeneration, type 2 diabetes and other metabolic disorders.Type: ApplicationFiled: March 6, 2018Publication date: December 26, 2019Inventors: Sven Franciscus Anna Van Brandt, Henricus Jacobus Maria Gijsen, Ann Marleen Vos, Daniel Oehlrich